Industry Satellite Symposia
6:15 p.m. - 6:45 p.m. - Registration and Dinner
6:45 p.m. - 8:15 p.m. - Symposium
Hyatt Regency McCormick Place, Regency Ballroom CDE
Dinner will be provided.
Accreditation: This activity will be planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.
CME Credits: The Medical Learning Institute, Inc. designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Participation information will be shared with ABIM through the ACCME’s Program and Activity Reporting System (PARS). Blinded individual or aggregated participant data may be shared with the funder of the activity.
Target Audience: The activity has been designed to meet the educational needs of radiation oncologists, medical oncologists, surgeons, neuro-oncologists, and other healthcare professionals involved in the care of patients with NSCLC and CNS metastases.
Overview: Central nervous system (CNS) metastases occur commonly in patients with lung cancer, and those patients with epidermal growth factor receptor (EGFR)-mutant non–small cell lung cancer (NSCLC) are particularly prone to their development. Treatment of brain metastases is challenging, and there are varied perspectives among different specialists about the best approach—if, when, and how to use local therapies, systemic therapies, or different treatment modalities in combination or sequence, etc. Clinical trials are underway to try to answer some of these critical questions about which treatment strategies yield the best results for these patients. This PeerView Live MasterClass and Practicum educational activity will convene a panel of multidisciplinary experts in EGFR-mutant lung cancer and CNS metastases to discuss the evolving evidence, clinical challenges, and practicalities of patient care. Real cases will be debated from multiple perspectives, with emphasis on information and guidance relevant for radiation oncologists. Come meet the experts and join the discussion!
Upon completion of this activity, participants should be better able to:
The asset you are trying to access is locked. Please enter your access key to unlock.